PharmaCyte Biotech Inc (PMCB)

[Triple9]

July 7: J&J announces the end of it's stem cell partnership with Capricor.
http://www.fiercebiotech.com/biotech/capricor-yo-yos-as-j-j-dumps-stem-cell-partnership

~July 20: $PMCB's Ken Waggoner posts to his FB page (now set to private) "Canadians will soon outnumber Americans at PharmaCyte" i.e., more Canadians than Americans i.e., Canadians will be in control. KW post pics from the Fairmont Hotel in Toronto, which is 5 minutes away from J&J's JLabs Toronto incubator site and 15 minutes away from Janssen's office.

July 27: Bavarian Nordic signs a "license and collaboration agreement" with Janssen under which J&J made an equity investment of $33 Million in Bavarian Nordic and Janssen will "conduct all clinical development and, subject to regulatory approval, be responsible for registration, distribution and commercialization of any potential new vaccine regimens worldwide. Bavarian Nordic will receive an upfront payment and be eligible to receive milestone payments based upon the achievement of specified development, regulatory and sales milestones and tiered royalties on future worldwide sales." Bavarian Nordic releases public information about the partnership on August 9.
https://finance.yahoo.com/news/bavarian-nordic-announces-subscription-price-182601887.html

August 8: Austrianova's FB page states: "Exciting new opportunities and partner for encapsulated stem cell applications - watch this space!"
https://www.facebook.com/austrianova/posts/1616942591670942

If I were a betting man, I'd wager Austrianova's stem cell biologics have replaced Capricor's in Janssen's massive pharma pipeline.

I'd also wager that $PMCB has signed a deal with Janssen because PharmaCyte holds exclusive rights to the CiaB pancreatic and diabetes treatments. If such a deal is a typical Janssen deal we should expect an equity investment into $PMCB along with license and collaboration agreements under which development of the pancreatic cancer CiaB and diabetes CiaB's biologics are Controlled and conducted by Janssen in return for generous milestone and generous royalty payments.